Atara Biotherapeutics Inc
NASDAQ:ATRA
ROE
Return on Equity
ROE, or Return on Equity, is a key financial ratio that measures a company's profitability. Specifically, it measures how many dollars of profit are generated for each dollar of shareholder's equity. A higher ROE indicates better financial performance and effective use of capital, making it a valuable metric for investors assessing a company's earning potential.
ROE Across Competitors
| Country | Company | Market Cap | ROE | ||
|---|---|---|---|---|---|
| US |
|
Atara Biotherapeutics Inc
NASDAQ:ATRA
|
46.2m USD |
20%
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
115%
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
328.7B USD |
88%
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
155B USD |
106%
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
137B USD |
33%
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
113.6B USD |
-6%
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
-877%
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
119.6B AUD |
15%
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
53B USD |
16%
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
-28%
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
39.7B USD |
519%
|
Atara Biotherapeutics Inc
Glance View
Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which pioneers the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. The company is headquartered in South San Francisco, California and currently employs 578 full-time employees. The company went IPO on 2014-10-16. The firm is a developer of T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune disease. Its platform leverages the biology of EBV T cells and has the capability to treat a range of EBV-driven diseases or other serious diseases through engineered chimeric antigen receptors (CARs) or T-cell receptors (TCRs). The Company’s pipeline products include Tab-cel, ATA188, ATA2271, ATA3271 and ATA3219. The Company’s T-cell immunotherapy, tab-cel (tabelecleucel), is in Phase III development for patients with EBV-driven post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed rituximab or rituximab plus chemotherapy, as well as other EBV-driven diseases. Its ATA188 is a T-cell immunotherapy for the treatment of multiple sclerosis.
See Also
ROE, or Return on Equity, is a key financial ratio that measures a company's profitability. Specifically, it measures how many dollars of profit are generated for each dollar of shareholder's equity. A higher ROE indicates better financial performance and effective use of capital, making it a valuable metric for investors assessing a company's earning potential.
Based on Atara Biotherapeutics Inc's most recent financial statements, the company has ROE of 20.4%.
You don't have any saved screeners yet